CORCEPT THERAPEUTICS INC Lease, Cost
CORCEPT THERAPEUTICS INC (CORT) reported Lease, Cost of $1.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-07-29
- CORCEPT THERAPEUTICS INC lease, cost for the quarter ending 2026-06-30 was $1.00M, a 66.67% increase year-over-year.
- CORCEPT THERAPEUTICS INC lease, cost for the quarter ending 2026-03-31 was $700.00K, a 0.00% change year-over-year.
- CORCEPT THERAPEUTICS INC lease, cost for the quarter ending 2025-12-31 was -$1.20M, a 233.33% decline year-over-year.
- CORCEPT THERAPEUTICS INC lease, cost for the quarter ending 2025-09-30 was $600.00K, a 14.29% decline year-over-year.
- CORCEPT THERAPEUTICS INC lease, cost for fiscal 2024 was $3.00M, a 25.00% increase from fiscal 2023.
- CORCEPT THERAPEUTICS INC lease, cost for fiscal 2023 was $2.40M, a 4.35% increase from fiscal 2022.
- CORCEPT THERAPEUTICS INC lease, cost for fiscal 2022 was $2.30M.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month | Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $1.00M 10-Q · filed 2026-07-29 | $1.70M 10-Q · filed 2026-07-29 | $500.00K derived: sum of 3 quarters · filed 2026-07-29 | $1.10M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2026-03-31 | $700.00K 10-Q · filed 2026-04-30 | -$500.00K derived: sum of 2 quarters · filed 2026-04-30 | $100.00K derived: sum of 3 quarters · filed 2026-04-30 | $700.00K derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-12-31 | -$1.20M derived: 10-Q 12 month − 10-Q 9 month · filed 2026-04-30 | -$600.00K derived: sum of 2 quarters · filed 2026-04-30 | $0.00 derived: sum of 3 quarters · filed 2026-07-29 | $700.00K 10-Q · filed 2026-04-30 | $2.50M 10-K · filed 2026-02-24 |
| 2025-09-30 | $600.00K 10-Q · filed 2025-11-04 | $1.20M derived: sum of 2 quarters · filed 2026-07-29 | $1.90M 10-Q · filed 2025-11-04 | $2.80M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-06-30 | $600.00K 10-Q · filed 2026-07-29 | $1.30M 10-Q · filed 2026-07-29 | $2.20M derived: sum of 3 quarters · filed 2026-07-29 | $2.90M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-03-31 | $700.00K 10-Q · filed 2025-05-05 | $1.60M derived: sum of 2 quarters · filed 2026-02-24 | $2.30M derived: sum of 3 quarters · filed 2026-02-24 | $3.10M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.60M derived: sum of 2 quarters · filed 2026-02-24 | $2.40M derived: sum of 3 quarters · filed 2026-02-24 | $3.00M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $700.00K 10-Q · filed 2025-11-04 | $1.50M derived: sum of 2 quarters · filed 2025-11-04 | $2.10M 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | $800.00K 10-Q · filed 2025-07-31 | $1.40M 10-Q · filed 2025-07-31 | |||
| 2024-03-31 | $600.00K 10-Q · filed 2025-05-05 | ||||
| 2023-12-31 | $2.40M 10-K · filed 2026-02-24 | ||||
| 2022-12-31 | $2.30M 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |